Other substances

CoV2-09

An anti-Spike (SARS-CoV-2) human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

CoV2-09 is a human monoclonal antibody targeting Spike protein RBD (SARS-CoV-2). It was identified using single-chain variable fragment phage display technique. Its epitope overlaps with the CoV2-16's one and the antibody competes with ACE2 receptor (Ku et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Spike protein Biophysical assay Animal model In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; Vero cells; Vero E6 cells; TMPRSS2-expressing Vero E6 cells; BALB/c mice; SARS-CoV-2 S pseudovirus; SARS-CoV-2 mouse-adapted strain CMA-3; SARS-CoV-2 clinical isolate USA/WA1/2020 12.12

Binds to RBD of SARS-CoV-2 Spike protein and neutralizes SARS-CoV-2 live virus in vitro with NT50 of 0.66 μg/ml.

 Jan/20/2021
Export (.csv)